Literature DB >> 12801932

Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells.

Guriqbal Basi1, Normand Frigon, Robin Barbour, Tam Doan, Grace Gordon, Lisa McConlogue, Sukanto Sinha, Michelle Zeller.   

Abstract

The deposition of extracellular beta-amyloid peptide (A beta) in the brain is a pathologic feature of Alzheimer's disease. The beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), an integral membrane aspartyl protease responsible for cleavage of amyloid precursor protein (APP) at the beta-site, promotes A beta production. A second integral membrane aspartyl protease related to BACE1, referred to as beta-site amyloid precursor protein cleaving enzyme 2 (BACE2) has also been demonstrated to cleave APP at the beta-cleavage site in transfected cells. The role of endogenous BACE2 in A beta production remains unresolved. We investigated the role of endogenous BACE2 in A beta production in cells by selective inactivation of its transcripts using RNA interference. We are able to reduce steady state levels for mRNA for each enzyme by >85%, and protein amounts by 88-94% in cells. Selective inactivation of BACE1 by RNA interference results in decreased beta-cleaved secreted APP and A beta peptide secretion from cells, as expected. Selective inactivation of BACE2 by RNAi results in increased beta-cleaved secreted APP and A beta peptide secretion from cells. Simultaneous targeting of both enzymes by RNA interference does not have any net effect on A beta released from cells. Our observations of changes in APP metabolism and A beta are consistent with a role of BACE2 in suppressing A beta production in cells that co-express both enzymes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12801932     DOI: 10.1074/jbc.M300169200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  BACE2 expression increases in human neurodegenerative disease.

Authors:  Christopher J Holler; Robin L Webb; Ashley L Laux; Tina L Beckett; Dana M Niedowicz; Rachel R Ahmed; Yinxing Liu; Christopher R Simmons; Amy L S Dowling; Angela Spinelli; Moshe Khurgel; Steven Estus; Elizabeth Head; Louis B Hersh; M Paul Murphy
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

2.  Functional domains of the BACE1 and BACE2 promoters and mechanisms of transcriptional suppression of the BACE2 promoter in normal neuronal cells.

Authors:  Debomoy K Lahiri; Bryan Maloney; Yuan-Wen Ge
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

3.  Characterization of the human beta-secretase 2 (BACE2) 5'-flanking region: identification of a 268-bp region as the basal BACE2 promoter.

Authors:  Bryan Maloney; Yuan-Wen Ge; Nigel H Greig; Debomoy K Lahiri
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 4.  Beta-secretase: structure, function, and evolution.

Authors:  Chitra Venugopal; Christina M Demos; K S Jagannatha Rao; Miguel A Pappolla; Kumar Sambamurti
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

Review 5.  Targeting the β secretase BACE1 for Alzheimer's disease therapy.

Authors:  Riqiang Yan; Robert Vassar
Journal:  Lancet Neurol       Date:  2014-02-17       Impact factor: 44.182

6.  BACE1 and BACE2 enzymatic activities in Alzheimer's disease.

Authors:  Rachel R Ahmed; Christopher J Holler; Robin L Webb; Feng Li; Tina L Beckett; M Paul Murphy
Journal:  J Neurochem       Date:  2009-12-04       Impact factor: 5.372

Review 7.  Linking vascular disorders and Alzheimer's disease: potential involvement of BACE1.

Authors:  Sarah L Cole; Robert Vassar
Journal:  Neurobiol Aging       Date:  2008-03-04       Impact factor: 4.673

8.  Evaluation of BACE1 Silencing in Cellular Models.

Authors:  Malgorzata Sierant; Katarzyna Kubiak; Julia Kazmierczak-Baranska; Masaki Warashina; Tomoko Kuwabara; Barbara Nawrot
Journal:  Int J Alzheimers Dis       Date:  2009-07-14

9.  Asynchronous evolutionary origins of Aβ and BACE1.

Authors:  D Blaine Moore; Madelyn A Gillentine; Nathalie M Botezatu; Kyle A Wilson; Ashley E Benson; James A Langeland
Journal:  Mol Biol Evol       Date:  2013-12-19       Impact factor: 16.240

10.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.